MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody

Targeting cancer antigens by T cell-engaging bispecific antibody (BiAb) or chimeric antigen receptor T cell therapy has achieved successes in hematological cancers, but attempts to use it to fight solid cancers have been disappointing, in part due to antigen escape. MEK inhibitor had limited activit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Li, Hongjian, Huang, Cheng, Zhang, Zongliang, Feng, Yunyu, Wang, Zeng, Tang, Xin, Zhong, Kunhong, Hu, Yating, Guo, Gang, Zhou, Liangxue, Guo, Wenhao, Xu, Jianguo, Yang, Hui, Tong, Aiping
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7477310/
https://ncbi.nlm.nih.gov/pubmed/32984002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.01527
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados